According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “
A number of other equities research analysts have also weighed in on SCPH. HC Wainwright initiated coverage on shares of Scpharmaceuticals in a report on Tuesday, October 15th. They set a “buy” rating and a $13.00 price objective on the stock. ValuEngine raised shares of Scpharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 21st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.17.
Scpharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. As a group, sell-side analysts anticipate that Scpharmaceuticals will post -1.66 EPS for the current year.
In other Scpharmaceuticals news, CEO John H. Tucker purchased 5,000 shares of the stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $5.24 per share, with a total value of $26,200.00. Following the completion of the acquisition, the chief executive officer now owns 5,000 shares in the company, valued at $26,200. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.07% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of SCPH. Morgan Stanley raised its position in shares of Scpharmaceuticals by 32.0% in the second quarter. Morgan Stanley now owns 13,633 shares of the company’s stock worth $43,000 after acquiring an additional 3,306 shares during the period. Matisse Capital acquired a new position in shares of Scpharmaceuticals in the third quarter worth about $86,000. Paloma Partners Management Co acquired a new position in shares of Scpharmaceuticals in the second quarter worth about $96,000. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Scpharmaceuticals by 55.8% in the second quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock worth $118,000 after acquiring an additional 13,225 shares during the period. 40.67% of the stock is currently owned by institutional investors.
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Featured Story: What is a stock split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.